The subcellular distribution of calcium and the effects of calcium-antagonists as evaluated with a combined oxalate-pyroantimonate technique.
D000818:Animals; D000965:Antimony; D001158:Arteries / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D002118:Calcium / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002936:Cinnarizine / Q000031:analogs & derivatives / Q000494:pharmacology*; D004285:Dogs; D005444:Flunarizine; D008013:Lidoflazine / Q000494:pharmacology*; D008854:Microscopy, Electron; D010070:Oxalates; D010545:Peroxides; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats; D013194:Staining and Labeling; D014665:Vasodilator Agents / Q000494:pharmacology*
D010070:Oxalates; D010545:Peroxides; D010879:Piperazines; D014665:Vasodilator Agents; C009133:pyroantimonate; D002936:Cinnarizine; D000965:Antimony; D008013:Lidoflazine; D005444:Flunarizine; D002118:Calcium